Clindamycin 4-phosphate

The composition of matter patents in the United States issued to The Upjohn Company on clindamycin phosphate and hydrochloride expired at the end of 1986 and in early 1987, respectively. Since then, these compounds have been available genericaHy from more than two dozen companies in the United States alone (101,102). 

Admixture incompatibilities - Magnesium sulfate in solution may result in a precipitate formation when mixed with solutions containing Alcohol (in high concentrations) alkali carbonates and bicarbonates alkali hydroxides arsenates barium calcium clindamycin phosphate heavy metals hydrocortisone sodium succinate phosphates polymyxin B sulfate procaine hydrochloride salicylates strontium tartrates. 

Lincos amides clindamycin hydochloride clindamycin palmitate hydrochloride clindamycin phosphate lincomycin hydrochloride monohydrate... 

Several systemic antibiotics that have traditionally been used in the treatment of acnevulgaris have been shown to be effective when applied topically. Currently, four antibiotics are so utilized clindamycin phosphate, erythromycin base, metronidazole, and sulfacetamide. The effectiveness of topical therapy is less than that achieved by systemic administration of the same antibiotic. Therefore, topical therapy is generally suitable only in mild to moderate cases of inflammatory acne. 

CLEOCIN T topical solution and CLEOCIN T topical lotion contain clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per milliliter. CLEOCIN T topical gel contains clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per gram. Each CLEOCIN T topical solution pledget applicator contains... 

Topical treatment of inflammatory acne vulgaris Benzoyl peroxide Clindamycin phosphate Duac Carbomer 940/sodium hydroxide Aqueous... 

Gyno-Daktarin 200 mg vaginal capsule (Janssen-Cilag) miconazole nitrate Cleocin (Pharmacia) clindamycin phosphate... 

L. W. Brown, High-pressure liquid chromatographic assays for clindamycin, clindamycin phosphate, and clindamycin palmitate, J. Pharm. Sci., 57 1254 (1978). 

Clindamycin Solutions of clindamycin salts are incompatible with alkaline doses or other drugs that are unstable at low pH. Clindamycin phosphate is not compatible with some rubber packing materials. pH-dependent degradation was reported with clindamycin, and phosphate salt was found to be most stable. Therapy with clindamycin should be stopped if diarrhea or colitis are found. The patient should be treated with other antibiotics. Clindamycin potentiates the actions of neuromuscular-blocking agents, opioids, and the antagonistic action of parasympathomimetics. 

Clindamycin phosphate Antibiotic Vaginosis caused by bacteria Clindesse 2.0... 

Clindamycin phosphate Minimum fill, pH (4.5 and 6.5), and assay Tight containers... 

Clindamycin phosphate (vag) Antibiotic Certain types of vaginal infection (e.g., bacterial vaginosis) Cleocin T 1.0... 

Levinson, R. S., Mitan, S. J., Steinmetz, J. I., Gattermeir, D. J., Schumacher, R. J., and Joffrion, J. L. (2005), An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations, Clin. Ther., 27,1894-1900. 

Borin, M. T. (1990), Systemic absorption of clindamycin following intravaginal application of clindamycin phosphate 1% cream,/. Clin. Pharmacol., 30, 33-38. 

Clidinium bromide, 473 Clinazine, 1044 Clindamycin, 473 Clindamycin hydrochloride, 473 Clindamycin palmitate hydrochloride, 473 Clindamycin phosphate, 474... 

In a one-year retrospective study at a tertiary hospital in Spain, 17% of 148 episodes of diarrhea associated with C. difficile developed after therapy with clindamycin (26). The possible association of toxin-positive C. difficile-induced colitis and the use of clindamycin phosphate vaginal cream for bacterial vaginosis has been reported in a 25-year-old white woman postpartum (27). 

In a 38-year-old non-atopic man, a generalized prurigi-nous maculopapular eruption with hp edema and facial erythema developed after 10 days of treatment with oral clindamycin phosphate (300 mg qds) and amoxicillin (500 mg qds) for bronchopneumonia (24). A patch test was positive 2 months later for clindamycin phosphate but negative for peniciUin, amoxiciUin, ampiciUin, and erythromycin. Prick tests and intradermal tests were all negative. Oral rechallenge with chndamycin phosphate 300 mg was positive. 

Meadoweroft AM, Diaz PR, Latham GS. Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. Ann Pharmacother 1998 32(3) 309-11. 

Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986 122(5) 583-4. 

Bndamydn Phosphate, USP. Clindamycin phos-I phate (Cleocin Phosphate) is the 2-phosphate ester of clinda-myviii. It exists as a zwittcrionic structure that is very soluble in water. It is intended for parenteral (intravenous or intramuscular) administration for the treatment of serious infec-iious and instances when oral administration is not feasible. Solutions of clindamycin phosphate are stable at room tem-pnatute for 16 days and for up to 32 days when refrigerated. 

Budsberg, S.C., Kemp, D.T. Wolski, N. (1992) Pharmacokinetics of clindamycin phosphate in dogs after single intravenous and intramuscular administrations. American Journal of Veterinary Research, 53, 2333-2336. 

---